Grace Therapeutics (GRCE) Fundamental Analysis: Revenue, Earnings & Valuation

6.32 / 10

Outperform

Fundamental rating is Outperform with a 6.3/10 score. Key strengths include high interest coverage, strong inventory turnover, rapid revenue growth, and favorable Revenue‑MV and Asset‑MV differentials. The main weakness is a low PB‑ROE metric, dragging the overall quality.

Analysis Checks(9/10)

Revenue-MV

Value-0.11

Score3/3

Weight28.43%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value134.00

Score2/3

Weight0.39%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-3.24%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value35.85

Score3/3

Weight5.28%

1M Return1.67%

PB-ROE

Value-0.41

Score1/3

Weight22.98%

1M Return7.56%

Long-term debt to working capital ratio (%)

Value0.17

Score3/3

Weight2.49%

1M Return0.87%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-3.30%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value177.16

Score2/3

Weight0.16%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-3.12%

1M Return-1.13%

Asset-MV

Value-0.53

Score3/3

Weight49.92%

1M Return11.61%

Is GRCE undervalued or overvalued?

GRCE scores 6.32/10 on fundamentals and holds a Discounted valuation at present. Backed by its -10.06% ROE, 0.00% net margin, -13.28 P/E ratio, 1.22 P/B ratio, and 73.04% earnings growth, these metrics solidify its Outperform investment rating.